Apellis Pharmaceuticals, Inc. (APLS) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a negative opinion for Pegcetacoplan for geographic atrophy or GA.
The European Commission has granted conditional marketing authorization to adagrasib for use in adult patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation whose disease progressed following at least 1 prior systemic treatment.